Potential uremic toxins modulate energy metabolism of cardiac myocytes in vitro.
In the present study we investigated the direct effects of potential uremic toxins on the energy metabolism of cultured cardiac myocytes. High-energy phosphates were extracted with perchloric acid and determined by high performance liquid chromatography. Energy charge (calculated from the ratio of [ATP], [ADP] and [AMP] was significantly reduced by 20 mM urea and the combination of creatinine (5 mM) plus urea (200 mM). On the other hand, perfusion with culture media containing clinically relevant amounts of urea (20 mM) or creatinine (1 mM) increased the PCr/ATP ratio. This effect was more pronounced after application of an artificial uremic medium (consisting of uremic serum, urea, creatinine and cytokines) or high amounts of creatinine (5 mM) plus urea (200 mM). As contractility of myocytes is reduced due to application of uremic compounds or uremic serum, we attribute changes in contraction frequency or inotropy to dysregulation of calcium availability within the cell. In fact, the cardiodepressive action of uremic serum (2.5%) could be completely reversed by the calcium agonist, Bay K 8644, thus indicating disturbances in myocardial calcium homeostasis in uremia. Altered calcium regulation by uremic toxins might therefore be responsible for the observed changes in myocardial energy metabolism. These results might contribute to the understanding of the pathogenesis of cardiac damage in end-stage renal disease.
Weisensee
D
D
Medical Clinic IV, Department of Nephrology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany.
Schnaars
Y
Y
Schoeppe
W
W
Bereiter-Hahn
J
J
Löw-Friedrich
I
I
D000227:Adenine Nucleotides / Q000378:metabolism; D000818:Animals; D009202:Cardiomyopathies / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D002478:Cells, Cultured; D003404:Creatinine / Q000378:metabolism / Q000633:toxicity; D004734:Energy Metabolism / Q000187:drug effects; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D066298:In Vitro Techniques; D051379:Mice; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000166:cytology / Q000378:metabolism*; D014508:Urea / Q000378:metabolism / Q000633:toxicity; D014511:Uremia / Q000150:complications / Q000378:metabolism* / Q000503:physiopathology
D000227:Adenine Nucleotides; D014508:Urea; D003404:Creatinine